150 related articles for article (PubMed ID: 12972259)
1. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
[TBL] [Abstract][Full Text] [Related]
2. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
[TBL] [Abstract][Full Text] [Related]
3. Evolution of aldolase antibodies in vitro: correlation of catalytic activity and reaction-based selection.
Tanaka F; Fuller R; Shim H; Lerner RA; Barbas CF
J Mol Biol; 2004 Jan; 335(4):1007-18. PubMed ID: 14698295
[TBL] [Abstract][Full Text] [Related]
4. Multiple catalytic aldolase antibodies suitable for chemical programming.
Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
[TBL] [Abstract][Full Text] [Related]
5. Computational elucidation and validation of the three-dimensional structure of humanized aldolase catalytic antibody 38C2.
Jayakody RS; Jasin Arachchige LI; Japahuge A
J Biomol Struct Dyn; 2021 Apr; 39(7):2463-2477. PubMed ID: 32242499
[TBL] [Abstract][Full Text] [Related]
6. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
[TBL] [Abstract][Full Text] [Related]
7. A cofactor approach to copper-dependent catalytic antibodies.
Nicholas KM; Wentworth P; Harwig CW; Wentworth AD; Shafton A; Janda KD
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2648-53. PubMed ID: 11880619
[TBL] [Abstract][Full Text] [Related]
8. Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.
Gavrilyuk JI; Wuellner U; Barbas CF
Bioorg Med Chem Lett; 2009 Mar; 19(5):1421-4. PubMed ID: 19181522
[TBL] [Abstract][Full Text] [Related]
9. Antibody-catalyzed benzoin oxidation as a mechanistic probe for nucleophilic catalysis by an active site lysine.
Sklute G; Oizerowich R; Shulman H; Keinan E
Chemistry; 2004 May; 10(9):2159-65. PubMed ID: 15112204
[TBL] [Abstract][Full Text] [Related]
10. Enantioselective aldol cyclodehydrations catalyzed by antibody 38C2.
List B; Lerner RA; Barbas CF
Org Lett; 1999 Jul; 1(1):59-61. PubMed ID: 10822533
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the synthetic utility of aldolase antibody 38C2.
Mondal K; Ramesh NG; Roy I; Gupta MN
Bioorg Med Chem Lett; 2006 Feb; 16(4):807-10. PubMed ID: 16321532
[TBL] [Abstract][Full Text] [Related]
12. Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices.
Li LS; Rader C; Matsushita M; Das S; Barbas CF; Lerner RA; Sinha SC
J Med Chem; 2004 Nov; 47(23):5630-40. PubMed ID: 15509162
[TBL] [Abstract][Full Text] [Related]
13. In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy.
Shabat D; Lode HN; Pertl U; Reisfeld RA; Rader C; Lerner RA; Barbas CF
Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7528-33. PubMed ID: 11404472
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation.
Abraham S; Guo F; Li LS; Rader C; Liu C; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5584-9. PubMed ID: 17372220
[TBL] [Abstract][Full Text] [Related]
15. Highly efficient antibody-catalyzed deuteration of carbonyl compounds.
Shulman A; Sitry D; Shulman H; Keinan E
Chemistry; 2002 Jan; 8(1):229-39. PubMed ID: 11822454
[TBL] [Abstract][Full Text] [Related]
16. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst.
Rader C; Sinha SC; Popkov M; Lerner RA; Barbas CF
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5396-400. PubMed ID: 12702756
[TBL] [Abstract][Full Text] [Related]
17. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes.
Wagner J; Lerner RA; Barbas CF
Science; 1995 Dec; 270(5243):1797-800. PubMed ID: 8525368
[TBL] [Abstract][Full Text] [Related]
18. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope.
Barbas CF; Heine A; Zhong G; Hoffmann T; Gramatikova S; Björnestedt R; List B; Anderson J; Stura EA; Wilson IA; Lerner RA
Science; 1997 Dec; 278(5346):2085-92. PubMed ID: 9405338
[TBL] [Abstract][Full Text] [Related]
19. Reaction properties of catalytic antibodies encapsulated in organo substituted SiO2 sol-gel materials.
Kato K; Saito T; Seelan S; Tomita M; Yokogawa Y
J Biosci Bioeng; 2005 Oct; 100(4):478-80. PubMed ID: 16310742
[TBL] [Abstract][Full Text] [Related]
20. Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis.
List B; Barbas CF; Lerner RA
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15351-5. PubMed ID: 9860972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
